Core A, the Administrative Core, will serve as the administrative and organizational structure that coordinates the activities of the Program Project Grant, PPG, and so facilitate its scientific mission. The goals of the Core A are to: ensure a programmatic, multidisciplinary focus, facilitate intra- and extra PPG communications and relieve PI and Core Directors of the common administrative activities need to manage the PPG. Dr. Schneck, Core Director, is an experienced administrator who has overseen development of the program since inception over two years ago and will continue to oversee daily operations of the program including coordinating the bi-monthly Research-ln-Progress meetings. Three leaders in the field of T cell biology have agreed to serve on the SAC of this program project. They are: Dr. William Paul (Chief Laboratory of Immunology, NIAID, NIH Bethesda, MD);Dr. Ronald Schwartz (Chief Laboratory of Cellular and Molecular Immunology, NIAID, NIH, Bethesda MD);and Dr. Gary Koretzky (Leonard Jarett Professor of Pathology and Laboratory Medicine, Investigator and Director, Signal Transduction Program of the Abramson Family Cancer Research Institute, Chief, Division of Rheumatology and Department of Medicine, U Penn, Philadelphia, PA). The Administrative Core will be responsible for arranging the annual meeting with the Scientific Advisory Committee, SAC. Core A will oversee the integration of PPG activities and seminars with other the Hopkins programs including: Graduate Program in Immunology, Graduate Program in Pathology, JHMI Oncology Center, and JHMI HiTs center as needed. Core A will further assist PI and Core Directors in serving as the direct liaison to the NIH and SAC. These functions will serve to maximize efficiency and minimize administrative responsibilities of the Project Leaders, PL, allowing them to focus on their scientific mission.
| Schappert, Anna; Schneck, Jonathan P; Suarez, Lauren et al. (2018) Soluble MHC class I complexes for targeted immunotherapy. Life Sci 209:255-258 |
| Hickey, John W; Isser, Ariel Y; Vicente, Fernando P et al. (2018) Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties. Biomaterials 187:105-116 |
| Bettencourt, Ian A; Powell, Jonathan D (2017) Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation. J Immunol 198:999-1005 |
| Kosmides, A K; Meyer, R A; Hickey, J W et al. (2017) Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. Biomaterials 118:16-26 |
| Tiper, Irina V; Temkin, Sarah M; Spiegel, Sarah et al. (2016) VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. Clin Cancer Res 22:4249-58 |
| Pollizzi, Kristen N; Sun, Im-Hong; Patel, Chirag H et al. (2016) Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation. Nat Immunol 17:704-11 |
| Schütz, Christian; Varela, Juan Carlos; Perica, Karlo et al. (2016) Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells. Oncotarget 7:68503-68512 |
| Pollizzi, Kristen N; Patel, Chirag H; Sun, Im-Hong et al. (2015) mTORC1 and mTORC2 selectively regulate CD8? T cell differentiation. J Clin Invest 125:2090-108 |
| Perica, Karlo; Kosmides, Alyssa K; Schneck, Jonathan P (2015) Linking form to function: Biophysical aspects of artificial antigen presenting cell design. Biochim Biophys Acta 1853:781-90 |
| Bruns, Heiko; Bessell, Catherine; Varela, Juan Carlos et al. (2015) CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells. Clin Cancer Res 21:2075-83 |
Showing the most recent 10 out of 37 publications
